Elenbecestat

1388651-30-6

437.44

DMSO : >= 250 mg/mL

Neuronal Signaling

Elenbecestat (E2609) is a potent, orally bioavailable and CNS-penetrant BACE-1 inhibitor. Elenbecestat has the potential for Alzheimer's disease (AD) research^[1][2]. IC50 & Target: BACE-1^[1] In Vitro: Elenbecestat (E2609) is a potent BACE1 inhibitor with an IC₅₀ of ca.7 nmol/L in cell-based assay^[2].
Elenbecestat has been shown to reduce Ab production in the plasma, brain, and cerebrospinal fluid (CSF) of rodents^[2].
In Vivo: Elenbecestat (E2609; 0.3-30 mg/kg; p.o.) potently inhibits Ab1-40 and Ab1-42 production in the plasma and CSF of non-human primates^[2].
Elenbecestat displays the plasma half-life of 12-16 hours after once daily dosing^[1].